Medicinal cannabis company Althea Group Holdings (ASX:AGH) has announced record prescription numbers for their medicinal cannabis products in the month of July which has been consolidated by two major corporate partnerships. 

Prescriptions of the Group’s medical cannabis products increased by 334 patients in the month, bringing the total to 1,523 for the company which listed on the ASX in September 2018. 

“We are very pleased to have achieved a record-breaking month in July and entered into an agreement with Tetra Health, one of the leading medicinal cannabis-related service providers in Australia,” siad CEO Josh Fegan. 

“This agreement gives us access to a wider network of healthcare professionals as we continue on our mission of being the leading provider of high-quality medicinal cannabis products to patients in Australia.” 

This follows news of Althea’s first patient prescription in the UK last week, and has been identified by the company as a pipeline market. Althea intends to increase operations in the immediate future with the rollout of MyAccess Clinics located in Bristol and Glasgow which will provide UK patients with medicinal cannabis care, where conventional treatments have not been effective.

Over the next 2 years, Althea has flagged intentions to invest a further AUD $1.55m in three more MyAccess Clinics. 

Other services which will be provided under the MyAccess Clinics will be Project TWENTY21 which is the UK’s first national pilot for medical cannabis which aims to enroll 20,000 UK patients by the end of 2021.